Cibus, Inc. (CBUS) stock
Close on Nov 11, 2026Market cap $88.66MP/E –Yield –
Cibus, Inc. saw revenue fall 10.3% to $4.35M over the twelve months to Jun 30, 2026. Free cash flow was -$46.32M. At the latest close the market valued the company at $88.66M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $88.66M
- P/E ratio
- –
- Price to sales
- 20.40
- Price to book
- 5.99
- Dividend yield
- –
- Free cash flow yield
- -52.25%
Fundamentals
- Revenue
- $4.35M
- Net income
- -$98.19M
- EPS, diluted
- -$1.65
- Free cash flow
- -$46.32M
- Book value per share
- $0.19
- Diluted shares
- 77M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $1.15
- Open
- $1.18
- Day's range
- $1.12 – $1.21
- Volume
- 83,077
- Average volume (20 days)
- 75,289
- Beta (5 years)
- 1.74
- 52-week range
- $1.07 – $4.19
- RSI (14 days)
- 36.1
- Volatility (1 year)
- 106.4%
- Relative volume
- 0.43×
- WACC
- 13.5%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CBUS | S&P 500 | Difference | CBUS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.2% | -2.4% | −22.8 pts | ||
| 3 months | -38.9% | -1.2% | −37.8 pts | ||
| Year to date | -33.3% | +12.3% | −45.6 pts | ||
| 1 year | -12.1% | +12.4% | −24.6 pts | ||
| 3 years | -92.1% | +78.8% | −170.9 pts | -57.1% | +21.4% |
| 5 years | -99.3% | +75.2% | −174.5 pts | -63.4% | +11.9% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cibus filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About Cibus
Agricultural Chemicals
Cibus develops proprietary plant traits using precision gene editing technologies, particularly its Rapid Trait Development System and Trait Machine process. The enterprise focuses primarily on licensing productivity traits, such as weed management and disease resistance, directly into seed companies' elite germplasm for royalty fees. Key agricultural programs target rice herbicide tolerance alongside trait initiatives across crops like canola, soybean, and wheat. Beyond core crop genetics, the organization maintains a sustainable ingredients line producing bio-based fragrance products through yeast fermentation for consumer packaged goods companies. Its customer base includes global seed producers and multinational corporate partners.
Company profile, executives and historyCibus stock: common questions
What is Cibus's stock price?
CBUS closed at $1.16 on Nov 11, 2026, up 1.31% on the day. Over the past 52 weeks it traded between $1.07 and $4.19.
What is Cibus's market cap?
Cibus was worth $88.66M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CBUS's P/E ratio?
Cibus lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.65), so it has no meaningful P/E ratio.
How much revenue does Cibus make?
Cibus reported revenue of $4.35M for the twelve months to Jun 30, 2026, down 10.3% from a year earlier.
Does Cibus pay a dividend?
No. Cibus has not paid a cash dividend over the last twelve months.
When does Cibus report earnings next?
Cibus is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CBUS stock performed over the past year?
Including dividends, CBUS returned -12.1% over the past year, against +12.4% for the S&P 500.
How many CBUS shares are sold short?
3M shares were sold short at the latest FINRA report, 6.23% of the float, or 61.8 days of average trading volume.
Who are Cibus's competitors?
Companies most similar to Cibus by business, industry and size include EVGN, SNES, CSCIF, DYAI, BIOX.
See a number that looks wrong?